Zymeworks’ Zanidatamab Receives the US FDA’s Breakthrough Therapy Designation for the Treatment of Biliary Tract Cancer

Zymeworks’ Zanidatamab Receives the US FDA’s Breakthrough Therapy Designation for the Treatment of Biliary Tract Cancer

Zymeworks’ Zanidatamab Receives the US FDA’s Breakthrough Therapy Designation for the Treatment of Biliary Tract Cancer

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post